ClinConnect ClinConnect Logo
Search / Trial NCT06868368

Perceptions of Vaping Products

Launched by OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER · Mar 6, 2025

Trial Information

Current as of August 20, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is looking at how a specific type of vaping product, called 6-methyl nicotine (or metatine), affects young adults. Researchers want to understand how appealing these electronic cigarettes are and whether they might lead to more people using them. If you are between 21 and 34 years old, currently use e-cigarettes at least once a week, and can read and speak English, you may be eligible to participate.

Participants will need to agree to stop using any e-cigarettes for at least 12 hours before attending three lab sessions. During these sessions, you’ll provide information and help researchers learn more about vaping products. However, if you’ve recently had COVID-19, have certain serious health conditions, or are pregnant or breastfeeding, you may not be able to join the study. This trial is important because it can help us understand the risks and appeal of newer vaping products among young adults.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Aged 21-34 years
  • Current nicotine EC user (defined as ≥ weekly use over the past 3 months)
  • Willing to provide informed consent and abstain from using any e-cigarette at least 12 hours prior to the three lab sessions
  • Read and speak English
  • Exclusion Criteria:
  • Recently coronavirus disease 2019 (COVID-19) positive (defined as a positive test in the past 30 days) or a recent COVID-19 hospitalization (defined as a hospitalization within the past 6 months)
  • Unstable or significant psychiatric conditions (past and stable conditions will be allowed)
  • History of cardiac event or distress within the past 3 months
  • Have suffered from any serious lung disease or infection (e.g., tuberculosis, cystic fibrosis, or lung cancer) in the past 30 days
  • Are currently pregnant, planning to become pregnant, or breastfeeding (will be verified with urine pregnancy test)
  • Have hemophilia or another type of bleeding disorder
  • Are blind, severely visually impaired, deaf, hard of hearing, or have a severe motor disability

About Ohio State University Comprehensive Cancer Center

The Ohio State University Comprehensive Cancer Center (OSUCCC) is a leading institution dedicated to advancing cancer research, treatment, and education. As a National Cancer Institute-designated comprehensive cancer center, OSUCCC integrates cutting-edge research with clinical practice to develop innovative therapies and improve patient outcomes. With a collaborative approach that unites scientists and clinicians, OSUCCC focuses on personalized medicine, cancer prevention, and community outreach, striving to enhance the understanding of cancer biology and provide hope to patients through groundbreaking clinical trials and comprehensive care programs.

Locations

Columbus, Ohio, United States

Patients applied

0 patients applied

Trial Officials

Alayna P Tackett, PhD

Principal Investigator

Ohio State University Comprehensive Cancer Center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported